Video
Dr. Finn on Significance of Phase III Findings of Lenvatinib in HCC
Author(s):
Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).
Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).
This is a large, randomized, open-label phase III study of lenvatinib versus sorafenib, with a primary endpoint of noninferiority. Results showed that lenvatinib was found to be noninferior to sorafeni; additionally, lenvatinib is awaiting regulatory approval. There is buzz in the liver cancer community on how the agent would be incorporated into the landscape.
There may be subsets of patients in whom lenvatinib may perform better than sorafenib, Finn adds. It is an exciting time that, after 10 years, there may potentially be a new frontline option for these patients.
Brought to you in part by Eisai
